X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $16.88 | -21,000 | 3,756,233 | -1% | -$354,480 | |||||
2025-08-15 | LYB | Lyondellbasell Industries N.V. | Vanacker Peter Z. E. | CEO | S - Sale | $53.57 | -20,000 | 160,351 | -11% | -$1,071,422 | ||||||
| M | 2025-08-13 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $61.11 | -32,174 | 1,064,457 | -3% | -$1,966,286 | |||||
| M | 2025-08-14 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $2.00 | -4,900 | 4,483,315 | 0% | -$9,800 | |||||
| D | 2025-08-15 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $17.23 | -6,000 | 110,886 | -5% | -$103,380 | |||||
| D | 2025-08-15 | MDGL | Madrigal Pharmaceuticals, Inc. | Bate Kenneth | Dir | S - Sale+OE | $365.20 | -10,000 | 2,627 | -79% | -$3,652,009 | |||||
| M | 2025-08-13 | ARWR | Arrowhead Pharmaceuticals, Inc. | Hamilton James C | Chief Medical Officer | S - Sale | $20.00 | -10,000 | 262,122 | -4% | -$200,000 | |||||
| D | 2025-08-15 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale+OE | $46.56 | -10,000 | 97,130 | -9% | -$465,632 | |||||
| D | 2025-08-13 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale+OE | $38.03 | -4,861 | 103,613 | -4% | -$184,881 | |||||
| D | 2025-08-14 | CBT | Cabot Corp | Keohane Sean D | Pres, CEO | S - Sale+OE | $79.28 | -114,436 | 375,361 | -23% | -$9,072,094 | |||||
2025-08-13 | XERS | Xeris Biopharma Holdings, Inc. | Johnson John | Dir | S - Sale | $7.32 | -107,500 | 833,483 | -11% | -$786,459 | ||||||
2025-08-13 | ECL | Ecolab Inc. | Maclennan David | Dir | P - Purchase | $278.51 | +600 | 24,462 | +3% | +$167,108 | ||||||
| DM | 2025-08-13 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale+OE | $304.56 | -89,794 | 1,244,693 | -7% | -$27,347,635 | |||||
| D | 2025-08-13 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $300.45 | -11,013 | 252,018 | -4% | -$3,308,877 | |||||
| D | 2025-08-13 | ECL | Ecolab Inc. | Bradway Jennifer J | SVP, CORPORATE CONTROLLER | S - Sale+OE | $279.28 | -807 | 4,326 | -16% | -$225,379 | |||||
2025-08-13 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Pres | S - Sale | $53.57 | -3,060 | 108,214 | -3% | -$163,924 | ||||||
2025-08-14 | AMRX | Amneal Pharmaceuticals, Inc. | Shah Nikita | EVP | S - Sale | $9.29 | -71,694 | 267,235 | -21% | -$666,037 | ||||||
2025-08-13 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale | $15.00 | -13,712 | 19,631 | -41% | -$205,680 | ||||||
2025-08-14 | ABEO | Abeona Therapeutics Inc. | Crombez Eric | Dir | S - Sale | $6.93 | -4,718 | 42,427 | -10% | -$32,683 | ||||||
2025-08-15 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $7.36 | -15,000 | 462,666 | -3% | -$110,358 | ||||||
| M | 2025-08-13 | AMRX | Amneal Pharmaceuticals, Inc. | Konidaris Tasos | EVP, CFO | S - Sale | $9.33 | -499,730 | 122,152 | -80% | -$4,663,070 | |||||
| DM | 2025-08-12 | GEVO | Gevo, Inc. | Amorelli Angelo | Dir | S - Sale+OE | $1.95 | -200,000 | 2,942 | -99% | -$390,531 | |||||
2025-08-15 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $38.42 | -5,000 | 387,274 | -1% | -$192,100 | ||||||
2025-08-15 | LLY | Eli Lilly & Co | Montarce Lucas | EVP, CFO | P - Purchase | $691.79 | +715 | 14,685 | +5% | +$494,627 | ||||||
2025-08-13 | COLL | Collegium Pharmaceutical, Inc | Rubric Capital Management LP | 10% | S - Sale | $37.85 | -25,000 | 3,132,743 | -1% | -$946,250 | ||||||
2025-08-13 | ALDX | Aldeyra Therapeutics, Inc. | Alfieri Michael | Principal Financial Officer | P - Purchase | $5.30 | +2,500 | 2,500 | New | +$13,250 | ||||||
2025-08-06 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale | $42.73 | -30,914 | 65,806 | -32% | -$1,320,844 | ||||||
2025-08-13 | CLDX | Celldex Therapeutics, Inc. | Jimenez Freddy A. | SVP, GC | S - Sale | $24.77 | -771 | 34,962 | -2% | -$19,096 | ||||||
| D | 2025-08-13 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale+OE | $46.66 | -1,542 | 38,867 | -4% | -$71,950 | |||||
| D | 2025-08-14 | ALNY | Alnylam Pharmaceuticals, Inc. | Ausiello Dennis A | Dir | S - Sale+OE | $436.58 | -31,448 | 4,411 | -88% | -$13,729,536 | |||||
2025-08-14 | OLPX | Olaplex Holdings, Inc. | Dunleavy Catherine | COO, CFO | S - Sale | $1.40 | -101,798 | 1,966,848 | -5% | -$142,517 | ||||||
| D | 2025-08-13 | OLN | Olin Corp | Vermillion Teresa M | VP, Treasurer | S - Sale+OE | $21.11 | -6,000 | 17,340 | -26% | -$126,642 | |||||
2025-08-13 | NATR | Natures Sunshine Products Inc | Lanoy Jonathan David | SVP, Chief Accounting Officer | S - Sale | $16.51 | -5,000 | 50,051 | -9% | -$82,550 | ||||||
2025-08-14 | ACNT | Ascent Industries Co. | Hutter Christopher Gerald | Dir | S - Sale | $12.51 | -20,000 | 570,574 | -3% | -$250,200 | ||||||
| D | 2025-08-14 | FTK | Flotek Industries Inc/Cn/ | Ezell Ryan Gillis | CEO | S - Sale+OE | $12.26 | -87,187 | 156,855 | -36% | -$1,068,913 | |||||
2025-08-13 | NATR | Natures Sunshine Products Inc | Brower Nathan G | EVP, GC | S - Sale | $16.54 | -9,996 | 48,277 | -17% | -$165,334 | ||||||
| D | 2025-08-13 | BCRX | Biocryst Pharmaceuticals Inc | Heggie Theresa | Dir | S - Sale+OE | $8.51 | -70,000 | 65,352 | -52% | -$595,868 | |||||
2025-08-14 | BHC | Bausch Health Companies Inc. | Paulson John | Dir | P - Purchase | $9.00 | +34,721,118 | 70,755,869 | +96% | +$312,490,062 | ||||||
2025-08-13 | ALTO | Alto Ingredients, Inc. | Sneed James R | Chief Commercial Officer | P - Purchase | $1.06 | +3,176 | 432,397 | +1% | +$3,364 | ||||||
2025-08-12 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COFO, Secretary | S - Sale | $13.58 | -2,937 | 766,095 | 0% | -$39,884 | ||||||
| M | 2025-08-12 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale | $13.81 | -3,743 | 424,804 | -1% | -$51,684 | |||||
2025-08-14 | AMTX | Aemetis, Inc | Barton Francis P | Dir | S - Sale | $2.53 | -26,452 | 208,518 | -11% | -$67,016 | ||||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Moore John R | GC | S - Sale+OE | $13.39 | -2,098 | 10,214 | -17% | -$28,097 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Derakhshan Behrad | Chief Business Officer | S - Sale+OE | $13.39 | -2,491 | 23,645 | -10% | -$33,360 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Carruthers R Michael | CFO | S - Sale+OE | $13.39 | -1,428 | 86,162 | -2% | -$19,124 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $13.39 | -1,907 | 23,400 | -8% | -$25,539 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Koch Kevin | Pres, CEO | S - Sale+OE | $13.39 | -7,972 | 369,399 | -2% | -$106,764 | |||||
| D | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $13.39 | -2,862 | 25,361 | -10% | -$38,329 | |||||
| DM | 2025-08-12 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $96.29 | -28,088 | 116,915 | -19% | -$2,704,624 | |||||
| D | 2025-08-12 | RYTM | Rhythm Pharmaceuticals, Inc. | German Christopher Paul | Corporate Controller, CAO | S - Sale+OE | $95.00 | -1,500 | 922 | -62% | -$142,500 | |||||
| D | 2025-08-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $12.93 | -11,365 | 92,891 | -11% | -$146,987 | |||||
2025-08-12 | IDXX | Idexx Laboratories Inc /De | Erickson Michael G | EVP | S - Sale | $649.96 | -406 | 11,287 | -3% | -$263,813 | ||||||
2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | S - Sale | $85.71 | -4,975 | 40,794 | -11% | -$426,407 | ||||||
2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $85.93 | -56,960 | 411,219 | -12% | -$4,894,573 | ||||||
2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Gutwerg Ori | SVP, GENERICS | S - Sale | $86.53 | -5,873 | 84,024 | -7% | -$508,191 | ||||||
2025-08-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $88.87 | -400 | 76,474 | -1% | -$35,548 | ||||||
| M | 2025-08-12 | TSE | Trinseo Plc | Farrell Matthew | Dir | P - Purchase | $2.40 | +100,000 | 250,225 | +67% | +$240,028 | |||||
| D | 2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale+OE | $86.07 | -50,000 | 180,863 | -22% | -$4,303,500 | |||||
2025-08-12 | ANIP | Ani Pharmaceuticals Inc | Haughey Thomas | Dir | S - Sale | $85.93 | -19,341 | 36,521 | -35% | -$1,661,972 | ||||||
| DM | 2025-08-12 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $34.84 | -96,387 | 536,962 | -15% | -$3,357,842 | |||||
| D | 2025-08-13 | FTK | Flotek Industries Inc/Cn/ | Clement James Bond | CFO | S - Sale+OE | $12.74 | -45,732 | 95,439 | -32% | -$582,626 | |||||
| D | 2025-08-12 | ABBV | Abbvie Inc. | Saleki-Gerhardt Azita | EVP, CHIEF OPERATIONS OFFICER | S - Sale+OE | $198.42 | -42,370 | 183,812 | -19% | -$8,407,055 | |||||
| DM | 2025-08-12 | KNSA | Kiniksa Pharmaceuticals International, Plc | Malley Thomas | Dir | S - Sale+OE | $32.96 | -177,769 | 84,513 | -68% | -$5,859,815 | |||||
| D | 2025-08-12 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $5.25 | -5,500 | 0 | -100% | -$28,875 | |||||
2025-08-12 | INSM | Insmed Inc | Sharoky Melvin Md | Dir | S - Sale | $121.58 | -10,000 | 334,378 | -3% | -$1,215,800 | ||||||
| M | 2025-08-12 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $8.20 | -30,000 | 156,969 | -16% | -$246,149 | |||||
2025-08-13 | DSGN | Design Therapeutics, Inc. | William Arsani | Dir | S - Sale | $5.25 | -562,627 | 3,655,000 | -13% | -$2,953,792 | ||||||
2025-08-13 | LLY | Eli Lilly & Co | Alvarez Ralph | Dir | P - Purchase | $660.25 | +758 | 55,753 | +1% | +$500,473 | ||||||
| M | 2025-08-12 | KURA | Kura Oncology, Inc. | Wilson Troy Edward | Pres, CEO | P - Purchase | $6.06 | +50,000 | 630,162 | +9% | +$303,201 | |||||
2025-08-13 | KRO | Kronos Worldwide Inc | Nace Andrew B | EVP | P - Purchase | $5.83 | +3,000 | 19,453 | +18% | +$17,500 | ||||||
| A | 2025-05-09 | SXI | Standex International Corp/De/ | Cannon Charles H Jr | Dir | S - Sale | $154.67 | -2,779 | 16,687 | -14% | -$429,828 | |||||
| M | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $10.43 | -797 | 34,828 | -2% | -$8,313 | |||||
| M | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $10.43 | -185 | 8,849 | -2% | -$1,930 | |||||
| M | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $10.43 | -267 | 8,957 | -3% | -$2,785 | |||||
| M | 2025-08-11 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | S - Sale | $10.43 | -267 | 18,759 | -1% | -$2,785 | |||||
| D | 2025-08-11 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $5.28 | -618,175 | 994,619 | -38% | -$3,263,964 | |||||
| M | 2025-08-11 | BSLK | Bolt Projects Holdings, Inc. | Golden Arrow Sponsor, LLC | 10% | S - Sale | $3.14 | -45,197 | 1 | -100% | -$142,014 | |||||
| D | 2025-08-13 | WVE | Wave Life Sciences Ltd. | Henry Christian O | Dir | S - Sale+OE | $8.81 | -9,670 | 29,645 | -25% | -$85,193 | |||||
2025-08-13 | MXCT | Maxcyte, Inc. | Douglas Richard | Dir | P - Purchase | $1.39 | +80,000 | 230,577 | +53% | +$111,040 | ||||||
2025-08-13 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.83 | +100 | 168,062 | 0% | +$183 | ||||||
| M | 2025-08-11 | BHC | Bausch Health Companies Inc. | Paulson John | Dir | P - Purchase | $6.56 | +3,243,049 | 36,034,751 | +10% | +$21,267,731 | |||||
| D | 2025-08-12 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale+OE | $47.79 | -12,500 | 257,484 | -5% | -$597,326 | |||||
2025-08-11 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $48.59 | -30,000 | 490,757 | -6% | -$1,457,596 | ||||||
| D | 2025-08-11 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $90.08 | -3,984 | 8,509 | -32% | -$358,891 | |||||
| DM | 2025-08-11 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $63.62 | -60,000 | 733,719 | -8% | -$3,817,389 | |||||
| D | 2025-08-13 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $370.24 | -129,172 | 842,704 | -13% | -$47,825,149 | |||||
2025-08-12 | VTRS | Viatris Inc | Smith Scott Andrew | CEO | P - Purchase | $9.99 | +22,000 | 314,807 | +8% | +$219,740 | ||||||
2025-08-11 | ALDX | Aldeyra Therapeutics, Inc. | Machatha Stephen | Chief Development Officer | S - Sale | $5.15 | -22,073 | 221,799 | -9% | -$113,713 | ||||||
| D | 2025-08-11 | LGVN | Longeveron Inc. | Locklear Lisa | CFO | P - Purchase | $0.00 | +11,766 | 250,964 | +5% | +$0 | |||||
| D | 2025-08-11 | LGVN | Longeveron Inc. | Baluch Khoso | Dir | P - Purchase | $0.00 | +11,766 | 52,516 | +29% | +$0 | |||||
| DM | 2025-08-11 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $355.31 | -46,808 | 842,704 | -5% | -$16,631,386 | |||||
| DM | 2025-08-11 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale+OE | $355.32 | -46,463 | 1,116,584 | -4% | -$16,509,032 | |||||
| D | 2025-08-11 | IDXX | Idexx Laboratories Inc /De | Hunt Nimrata | EVP | S - Sale+OE | $656.53 | -1,200 | 18,193 | -6% | -$787,840 | |||||
2024-11-20 | TRUL | Trulieve Cannabis Corp. | Thronson Susan | Dir | P - Purchase | $6.30 | +3,968 | 50,845 | +8% | +$24,998 | ||||||
2024-11-21 | TRUL | Trulieve Cannabis Corp. | May Richard S. | Dir | P - Purchase | $6.05 | +1,610 | 570,096 | 0% | +$9,741 | ||||||
2025-08-11 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $23.98 | +471 | 6,827,604 | 0% | +$11,294 | ||||||
2025-08-12 | XERS | Xeris Biopharma Holdings, Inc. | Halkuff Dawn | Dir | S - Sale | $7.28 | -42,500 | 120,410 | -26% | -$309,226 | ||||||
2025-08-12 | AMRX | Amneal Pharmaceuticals, Inc. | Shah Nikita | EVP | S - Sale | $9.04 | -50,000 | 338,929 | -13% | -$452,000 | ||||||
2025-08-12 | AMRX | Amneal Pharmaceuticals, Inc. | Daly Jason B. | EVP, GC | S - Sale | $9.05 | -22,000 | 10,606 | -67% | -$199,100 | ||||||
2025-08-12 | AMRX | Amneal Pharmaceuticals, Inc. | Boyer Andrew S | EVP | S - Sale | $9.05 | -33,436 | 256,670 | -12% | -$302,596 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |